Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting ...

Novartis has agreed to pay up to $1.7 billion to license an experimental Alzheimer’s therapy from China-based SciNeuro, a ...

Under the deal, SciNeuro will receive $165m upfront and could earn up to $1.5bn in milestones.

Scientists have long been racking their brains for ways to treat Alzheimer’s disease, the most common type of dementia. Turns out that the answer may lie within our own brains. Researchers from ...

Early in Alzheimer’s disease, your brain can begin to change long before anyone notices a lost name or missed appointment.

After studying 140,000 versions of the Aβ42 peptide, scientists identified some of the earliest molecular interactions that drive the formation of harmful amyloid protein aggregates found in Alzheimer ...

A novel experimental anti-amyloid therapy lowered brain amyloid levels below the threshold of positivity in 92% of patients with early asymptomatic Alzheimer’s disease (AD) treated at the highest test ...

ARIA is the most common side effect of anti–amyloid-beta MAB treatment. MABs increase vascular permeability, which can result in inflammation and leakage of proteinaceous fluid and blood products, ...